Liver Disease

Latest News

Patient in the hospital - Tyler Olson -stock.adobe.com.jpg
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease

November 20th 2024

Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.

Blue FDA approved stamp | Imaged credit: Olivier Le Moal - stock.adobe.com
FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis

March 14th 2024

AJMC
Statin Prescribing Patterns in Patient-Centered Medical Home Patients With NAFLD

August 17th 2023

Impact of Direct-Acting Antiviral Use for Chronic Hepatitis C on Health Care Costs in Medicaid: Economic Model Update

December 12th 2022

liver
Pathological Neutrophil Migration in Cirrhosis Linked to Increased Risk of AEs

November 30th 2022

Continuing Medical Education
View All
July 1st 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 1st 2025

Managed Care Insights on the Advances in the Eosinophilic Esophagitis Treatment Landscape

1.0 Credit / Gastroenterology, Immunology, Rare Diseases
July 1st 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health
July 1st 2025

Navigating the Changing Treatment Paradigm of Metabolic Dysfunction-Associated Steatohepatitis: A Guide for Managed Care Pharmacists

1.5 Credits / Endocrinology, Diabetes & Metabolism, Gastroenterology
July 1st 2025

Emerging Treatment Options for Inflammatory Bowel Disease: A Focus on IL-23 Pathway Inhibition

1.5 Credits / Gastroenterology, Immunology
July 1st 2025

Transforming Metabolic Dysfunction-Associated Steatohepatitis Management: Pharmacist Considerations for the Evolving Treatment Landscape

1.5 Credits / Gastroenterology
July 1st 2025

Innovations in Inflammatory Bowel Disease Therapy: How IL-23 Inhibitors Are Shaping Treatment and Managed Care Approaches

1.5 Credits / Gastroenterology, Immunology

More News

Reducing risk.
August 5th 2021

Fatty Liver Disease May Lower Risk of Cirrhosis, HCC in Patients With Comorbid Chronic Hepatitis B

Matthew Gavidia
Patients with concurrent fatty liver disease and chronic hepatitis B exhibited higher cumulative rates of hepatitis B surface antigen seroclearance and lower cumulative rates of cirrhosis and hepatocellular carcinoma (HCC) across a 10-year period.
hospital beds
August 2nd 2021

Developing a Model to Predict and Prevent Readmission in Patients With Cirrhosis

Laura Joszt, MA
Patient-reported outcome measures may have a small impact on predicting which patients with cirrhosis will be readmitted to the hospital.
Internal organs graphic
July 31st 2021

Review Examines Interaction Between 2 Distinct Liver Diseases

Allison Inserro
One diagnosis challenge is that there is no specific biomarker, either for autoimmune hepatitis (AIH) or metabolic-associated fatty liver disease (MAFLD), either alone or if they exist concurrently.
liver
July 29th 2021

Experts: Unified Global Approach Needed to Address NAFLD/NASH

Laura Joszt, MA
A new report is issuing a call to action to develop a global strategy to address the growing issue of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH).
Graphic of a liver
July 23rd 2021

Blood Test Could Identify Patients at Risk of Nonalcoholic Fatty Liver Disease, Study Says

Allison Inserro
The gold standard for diagnosing liver disease is a liver biopsy, but researchers are seeking a simpler way to identify those at risk, given the silent nature of early disease and rising incidence around the globe.
Better Studies Needed on Nutritional Supplementation in NAFLD
July 21st 2021

Better Studies Needed on Nutritional Supplementation in NAFLD

Laura Joszt, MA
The current available studies on nutritional supplementation in nonalcoholic fatty liver disease (NALFD) highlight the need for more high-quality randomized controlled trials.
doctor looking at notes
July 16th 2021

Survey Finds Physicians Lack Necessary Knowledge About NAFLD

Laura Joszt, MA
A survey of global physicians found a gap in knowledge of non-alcoholic fatty liver disease (NAFLD) despite the growing burden of the disease worldwide.
Review Discusses Growing Problem of Alcoholic Liver Disease
July 13th 2021

Review Discusses Growing Problem of Alcoholic Liver Disease

Allison Inserro
The problem of alcoholic liver disease is growing in the United States, and obtaining treatment is difficult.
Coffee
July 10th 2021

Caffeinated or Decaffeinated, Any Type of Coffee Appears to Protect the Liver

Coffee contains hundreds of chemical compounds and comes in several forms, and according to a recent study, has a protective effect on the liver, no matter what the type.
NAFLD Increases Mortality in Children and Young Adults Over the Long Term
July 8th 2021

NAFLD Increases Mortality in Children and Young Adults Over the Long Term

Laura Joszt, MA
A long-term Swedish study found that nonalcoholic fatty liver disease (NALFD) significantly increased mortality in children and young adults, particularly due to cancer, cardiometabolic disease, and liver disease.
Liver close-up
July 1st 2021

Study Identifies MAGEA3 as Novel Therapeutic Target in Hepatocellular Carcinoma

Lauren Massaro
Manipulating the expression of MAGEA3 can help block the growth of hepatocellular carcinoma.
Site Logo
May 28th 2021

Baffled by NAFLD: The Horse Might Be Out of the Barn but Should Not Take Us for a Ride

Zheng Che, MD A. Mark Fendrick, MD Elliot B. Tapper, MD
As awareness of nonalcoholic fatty liver disease (NAFLD) rises, it is essential to develop and implement a rigorously determined approach to identify patients who will, or will not, benefit from diagnostic evaluation.
Site Logo
May 28th 2021

Population-Based Return on Investment of Deploying Transient Elastography

Mazen Noureddin, MD Andrew Mackenzie, BS Elaine Zhao, BS Scott C. Howell, DO Michael Tunkelrott, MBA Ian Duncan, PhD
Deploying vibration-controlled transient elastography/controlled attenuation parameter devices at the population level is a financially advantageous solution to address the epidemic of fatty liver disease.
Data Show Those With Diabetes, NAFLD/NASH Have Twice Mortality Rate of Others in Medicare
June 14th 2019

Data Show Those With Diabetes, NAFLD/NASH Have Twice Mortality Rate of Others in Medicare

Mary Caffrey
Results were presented recently at the 79th Scientific Sessions of the American Diabetes Association.
<123

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo